Post hoc analysis reveals dupilumab effectiveness in prurigo nodularis, suggesting broad applicability.
Targeting type 2 inflammation with dupilumab was beneficial independent of age, gender, comorbidities and prior medication.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: